All In Biotech

Drug Trial Radar · NCT05577702

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoadjuvant Treatment in Chinese Patients With Resectable Stage II to IIIA Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

Mar 8, 2023

Primary completion

Dec 13, 2024

Study completion Jan 23, 2025

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with non-small cell lung cancer (NSCLC) that is able to be removed by surgery.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • TislelizumabDrug

    Administered as an intravenous infusion once every 3 weeks

  • OciperlimabDrug

    Administered as an intravenous infusion once every 3 weeks

  • AlcestobartDrug

    Administered as an intravenous infusion once every 3 weeks

  • CisplatinDrug

    75 mg/m\^2 administered as an intravenous infusion once every 3 weeks

  • CarboplatinDrug

    Administered as an intravenous infusion once every 3 weeks at an area under the curve (AUC) of 5 mg/mL/min

  • PemetrexedDrug

    500 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with non-squamous NSCLC

  • PaclitaxelDrug

    175 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with squamous NSCLC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathological Response (MPR) RateTime frame: At the time of surgery, approximately Week 16

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Guangzhou Medical Universitydatansha Hospital)

    Guangzhou, Guangdong, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanchang University Branch Xianghu

    Nanchang, Jiangxi, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.